Pacira BioSciences Inc
(STU:82P)
€
22.8
-0.60 (-2.56%)
Market Cap: 901.83 Mil
Enterprise Value: 1.08 Bil
PE Ratio: 220.08
PB Ratio: 1.59
GF Score: 75/100 Pacira Biosciences Inc at Barclays Global Healthcare Conference Transcript
Mar 12, 2020 / 01:00PM GMT
Release Date Price:
€28.8
(-7.10%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director
Good morning, everyone. Thank you for dialing in. My name is Balaji Prasad. I cover specialty pharma for Barclays. Continuing our health care conference virtually for day 3, we have with us today, Pacira Pharmaceuticals to -- for the 9 a.m. session. And from the management team side, we have with us Dave Stack, Chairman and CEO of Pacira; Ron Ellis, Senior Vice President, Corporate Strategy and Business Development; and Susan Mesco, Head of Investor Relations. Dave, Ron and Susan, good morning, and thank you for joining us.
David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO
Good morning, Balaji. And Charlie Reinhart, our CFO, is also with us here.
Charles A. Reinhart
Pacira BioSciences, Inc. - CFO
Good morning.
Questions & Answers
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director
So maybe a good point to start, Dave and Charlie, is the resounding guidance you gave
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot